Will I need ketamine forever?

Honestly, we do not know yet — and the published consensus statements are equally honest about that. Some patients taper off after a year of stable response and only return if symptoms come back. Others find that maintenance every four to eight weeks is what keeps them well, and they choose to continue indefinitely. The 2017 American Psychiatric Association consensus on ketamine for mood disorders explicitly notes that long-term maintenance dosing is under-studied. We reassess at every visit and let your response, not a fixed timeline, drive the plan.

How will I know it is time for a booster?

Most patients notice the early signs before any objective measure does. Sleep gets choppier. Irritability creeps back. Pain that had quieted starts asking for attention again. Mood may dip a few days before you can articulate why. We track these markers with you between visits, and we encourage patients to reach out at the first signal rather than waiting until they are back at baseline. Our companion article on how to tell if ketamine is not working covers the same warning signs in more detail.

Is monthly the standard maintenance cadence?

Monthly is a common starting point, but it is not a universal standard. The 2018 ASRA, AAPM, and ASA consensus guidelines on IV ketamine for chronic pain and the 2017 APA consensus on mood disorders both recommend individualized cadence based on symptom recurrence and functional outcomes. Real intervals at our clinic range from every two weeks for some patients to every eight to twelve weeks for others. The goal is the longest interval that keeps your response stable.

Can I do oral or intranasal maintenance instead of IV?

Different routes have different bioavailability, different evidence bases, and different regulatory status. FDA-approved Spravato (esketamine) is intranasal and has its own dosing schedule. Compounded oral ketamine has been the subject of FDA safety warnings about at-home use without monitoring. We do not recommend transitioning to a less-evidenced or less-monitored route purely for convenience. If a different route makes sense for your situation, we discuss it explicitly rather than substituting quietly.

What if I want to stop entirely?

That is a reasonable plan for many patients and we support it. We typically extend the interval gradually rather than cutting off treatment abruptly, watch for symptom return, and stay in touch for several months after the last infusion. If symptoms come back, restarting is usually straightforward — often a shorter mini-series rather than a full six-session induction. The decision to stop, continue, or restart belongs to you, with our clinical input.

Ketamine maintenance protocol explained: what happens after the induction series

Why there is no single “correct” maintenance schedule

Patients who have just finished a six-session induction often ask the same question on the way out the door. How often will I need to come back? The honest answer is that we do not know yet, not for you specifically. We know the shape of the question, the rough range of cadences other patients land on, and the warning signs that say it is time for a booster. We do not know your number until we watch how you do.

This is not evasion. It is what the published consensus statements actually say. The 2017 American Psychiatric Association consensus on ketamine in mood disorders, published in JAMA Psychiatry by Sanacora, Frye, McDonald, and colleagues, states plainly that long-term efficacy and optimal maintenance dosing for ketamine remain under-studied and that decisions should be individualized, with informed-consent discussion of the limited long-term safety data. The 2018 consensus guidelines on IV ketamine for chronic pain, published in Regional Anesthesia & Pain Medicine by Cohen, Bhatia, Buvanendran, and others on behalf of ASRA, AAPM, and ASA, reach a parallel conclusion: maintenance infusions should be guided by symptom recurrence and functional outcomes, with reassessment at every visit. No single fixed interval fits everyone.

Ketamine is FDA-approved as an anesthetic; its use for depression, PTSD, anxiety, and chronic pain is off-label. That regulatory reality is part of why maintenance protocols rely on consensus statements and clinical judgment rather than a single FDA-blessed schedule. The American Society of Ketamine Physicians, Psychotherapists & Practitioners (ASKP3) Standards of Care, updated in 2024, recommend the same individualized approach with documented criteria for continuation, taper, or discontinuation.

What “response” actually looks like at the end of induction

Before we can plan maintenance, we have to know whether induction worked. That sounds obvious, but the answer is rarely binary. Most responders describe a gradual lightening over the second and third week of the series rather than a single moment of breakthrough. Sleep usually shifts first. Then irritability softens. Then the constant background of rumination or pain quiets enough that you notice its absence. The neuroplastic window our brains open during a series tends to widen these changes for a few weeks after the last infusion.

If the changes do not arrive, that matters too. Our companion article on how to tell if ketamine is not working for you walks through what non-response looks like and the conversations that follow. Maintenance is not the right next step for someone who did not respond; the right next step is reassessment.

For partial responders, induction sometimes warrants extension before maintenance begins. Two extra sessions, sometimes four, can convert a partial response into a fuller one. We discuss the tradeoffs explicitly rather than defaulting to either path.

Typical cadence: weekly, biweekly, monthly, as-needed

For patients who respond well, the most common arc looks something like this. We are describing ranges, not a prescription.

Weeks 0–3: the induction series itself, typically six sessions clustered close together (every two to three days, then spacing out toward the end).
First booster: usually two to four weeks after the final induction session. Some patients need it sooner; some can stretch longer.
Months 1–3: a single booster every two to four weeks if response is holding. We adjust based on how you are doing, not the calendar alone.
Months 3–6: if benefit is stable, extend toward every four to six weeks.
Months 6–12: many patients reach every six to eight weeks. Some reach every eight to twelve weeks. A few can step further out than that.

The published evidence supports this ranging approach. Our deeper article on session counts walks through the studies that informed it. The principle is simple: the goal is the longest interval that keeps your response stable, not a fixed monthly slot. If you tighten too aggressively, you spend more than you need to. If you space too aggressively, you let symptoms creep back and lose ground.

How we taper, and how we know we have gone too far

Tapering is not the same as stopping. A taper is a deliberate stretching of the interval, watching at each step for signs that the response is slipping. We typically extend by one to two weeks at a time, then hold at the new interval for at least one cycle to confirm stability before stretching again.

Going too far looks like this. Sleep gets shorter and shallower a few days before your next scheduled booster. Mood drops in the last week of the cycle and lifts again right after the infusion, in a pattern that becomes recognizable. For pain patients, the pre-booster days bring stiffness and flares that the post-booster days do not. When this rebound pattern appears reliably, the interval is too long for your physiology and we tighten back to the last interval that held.

We document these patterns in your chart at each visit because they shape the next decision. The ASKP3 Standards of Care specifically call for ongoing reassessment with documented criteria for continuation, taper, or discontinuation. We take that seriously.

When to restart: warning signs that the response is fading

Patients who taper off entirely sometimes return six months or two years later. The triggers vary. A major stressor, a medical illness, a death, a postpartum period, or simply the slow re-arrival of symptoms that had stayed quiet for a long time. None of this means the original treatment failed. It means the underlying condition is chronic and the work of staying well is also chronic.

Restart is usually not a full induction. For most returning patients, a shorter mini-series (often three to four sessions) followed by spaced maintenance is enough to recover the prior response. We assess on intake whether a full induction or a mini-series fits better. The decision is clinical, not formulaic.

Integration therapy and the maintenance phase

Maintenance is not just about the infusion. The neuroplastic window between sessions is when most of the integration work actually happens, and the patients who do best in maintenance tend to be the ones who use that window deliberately. Ketamine-assisted psychotherapy in the days after a session, ongoing work with a trained integration therapist in Tennessee, journaling, somatic practices, and continued engagement with whatever was already working — therapy, exercise, sleep hygiene — all amplify and extend the response.

We do not expect every patient to do all of these. We do expect that the work of maintenance includes more than just showing up for the next infusion. Studies indicate that integration support is one of the modifiable factors that may extend interval length and reduce total session count over the year.

Total annual session counts patients tend to land on

Adding it up: a typical first year might include the six-session induction, then roughly six to twelve maintenance sessions, for an annual total in the range of twelve to eighteen. Some patients sit lower (closer to ten total). Some sit higher, particularly in the first year if symptoms are severe or relapsing. By year two, totals usually drop because intervals lengthen.

These are ranges from our clinic and from the published literature, not promises. Your number depends on your condition, your response pattern, and the rest of your treatment plan.

Cost planning for maintenance

Maintenance is the part of treatment most patients underestimate when they first plan their budget. Sessions at our clinic are $475 each, the same rate for induction and maintenance. Our note on what we charge and why walks through how we landed there. Insurance typically does not cover IV ketamine for off-label psychiatric or pain indications, so most patients pay out of pocket or use HSA/FSA funds.

We are happy to map out an estimated annual cost based on the cadence we expect, so you can plan rather than be surprised. If cost becomes a barrier mid-year, we would rather know early and discuss options than have you quietly stretch your interval past where it should be.

How we adjust if life events shift the picture

Major events deserve a real conversation rather than a routine check-in. A new diagnosis, a pregnancy, a medication change, a severe loss, surgery, a job loss, a hospitalization — any of these can change the maintenance plan. Sometimes we tighten the interval temporarily. Sometimes we pause and re-induct after the dust settles. Sometimes we just talk through what is happening and decide nothing changes.

What we do not do is run a script. The 2017 APA consensus, the 2018 ASRA/AAPM/ASA guidelines, and the ASKP3 Standards of Care all point in the same direction: maintenance is individualized, reassessed at every visit, and documented honestly. That is how we practice it. Our team is small enough that the same people see you across visits, so the continuity of judgment is real, not theoretical. Our process page walks through the steps in more detail if you want to see what a first visit looks like.

Honest about open questions: we do not yet have large randomized trials defining the perfect maintenance interval for any single condition, and the consensus statements we lean on say so directly. We work with the best available evidence and your individual response together, and we try not to pretend either part is more solid than it actually is.